TERIFLUNOMIDE DR.REDDY'S teriflunomide 14 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

teriflunomide dr.reddy's teriflunomide 14 mg tablet blister pack

dr reddys laboratories australia pty ltd - teriflunomide, quantity: 14 mg - tablet - excipient ingredients: maize starch; magnesium stearate; hyprolose; silicon dioxide; lactose monohydrate; sodium starch glycollate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; indigo carmine aluminium lake - teriflunomide dr.reddy's is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

POSACONAZOLE DR.REDDY'S posaconazole 100 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

posaconazole dr.reddy's posaconazole 100 mg modified release tablet blister pack

dr reddys laboratories australia pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: croscarmellose sodium; macrogol 400; hypromellose acetate succinate; silicon dioxide; triacetin; purified talc; hyprolose; iron oxide red; magnesium stearate; titanium dioxide; microcrystalline cellulose; hypromellose - posaconazole dr.reddy's (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. ,posaconazole dr.reddy's is also indicated for the: ,? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

DASATINIB DR.REDDY'S dasatinib 100 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib dr.reddy's dasatinib 100 mg film coated tablet blister pack

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 116 mg (equivalent: dasatinib, qty 100 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; lactose; silicon dioxide; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

DASATINIB DR.REDDY'S dasatinib 20 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib dr.reddy's dasatinib 20 mg film coated tablet blister pack

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 23.2 mg (equivalent: dasatinib, qty 20 mg) - tablet, film coated - excipient ingredients: lactose; croscarmellose sodium; triacetin; hydrogenated castor oil; magnesium stearate; titanium dioxide; silicon dioxide; microcrystalline cellulose; hypromellose - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

DASATINIB DR.REDDY'S dasatinib 70 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib dr.reddy's dasatinib 70 mg film coated tablet blister pack

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 81.2 mg (equivalent: dasatinib, qty 70 mg) - tablet, film coated - excipient ingredients: silicon dioxide; croscarmellose sodium; magnesium stearate; triacetin; titanium dioxide; microcrystalline cellulose; lactose; hydrogenated castor oil; hypromellose - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

DASATINIB DR.REDDY'S dasatinib 50 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib dr.reddy's dasatinib 50 mg film coated tablet blister pack

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 58 mg (equivalent: dasatinib, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hydrogenated castor oil; magnesium stearate; hypromellose; titanium dioxide; lactose; triacetin; silicon dioxide - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

DR DEB'S PERMETHRIN SOAK Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dr deb's permethrin soak

dr deb the travel doctor pty ltd - permethrin (25:75::cis:trans) - insecticide - fabric (cotton) - repellant treatment | mosquito nets - repellant treatment | cotton blend fabric | cotton blend net | cotton ne - insect | mosquito | adult mosquitoes

Bosentan Dr. Reddy’s 62.5mg Film-Coated Tablets United Kingdom - English - myHealthbox

bosentan dr. reddy’s 62.5mg film-coated tablets

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 62.5mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology